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Abstract 
Chronic cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) are associated with active hepatic fibrogenesis, and, 
ultimately, to the development of cirrhosis. However, the precise relationship between 
cholestasis, in its broad meaning, and liver tissue fibrosis is still poorly defined. 
Fibrogenesis is currently viewed as a dynamic process that appears strictly related to 
the extent and duration of parenchymal injury. This relationship is clearly evident in the 
presence of reiterative hepatocellular necrosis due to viral infection or alcohol abuse. 
It appears that “pure” intralobular intrahepatic cholestasis secondary to biliary 
secretory failure of the hepatocyte, in absence of hepatocellular damage, lobular 
inflammation and bile duct damage and/or proliferation, is not associated with marked 
and/or progressive liver tissue fibrosis. In contrast, marked and progressive liver tissue 
fibrosis always follows liver diseases characterized by chronic inflammatory bile duct 
damage as seen in PBC and PSC or chronic mechanical obstruction of the biliary tree.  
Overall, the fibrogenic process in these clinical conditions appears to be related to a 
more complex interaction between immune/inflammatory mechanisms, cytokine 
networks and the derangement of the homeostasis between epithelial and 
mesenchymal cells.  The elucidation of these mechanisms is indeed crucial for the 
identification of potential diagnostic and therapeutic targets. 
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Introduction 
Chronic liver diseases affecting bile ducts, namely primary biliary cholangitis (PBC) and 
primary sclerosing cholangitis (PSC), are characterized by the development of the so-called 
biliary fibrosis. In both conditions, biliary fibrosis originates from portal tracts and tends to 
expand with a portal-to-portal pattern. In more advanced stages, fibrosis extends to the 
lobular area and eventually leads to the development of biliary-type cirrhosis. It is important 
to stress that, in both PBC and PSC, the fibrogenic process is consequent to the involvement 
of small bile ducts within portal areas. In PBC, bile ducts are infiltrated by 
immune/inflammatory cells causing structural damage (Figure 1-A), ductopenia (Figure 1-B) 
and peri-biliary stromal expansion. In PSC the early features are represented by a peri-biliary 
inflammatory reaction.  The duct epithelium may show various degrees of atrophy and might 
even disappear, leaving a characteristic fibro-obliterative scar. Major bile ducts are often 
inflamed, ulcerated or dilated. These features are associated with concentric “onion-like” 
fibrosis (Figure 1-C) with a progressive obliteration of the bile ducts (Figure 1-D). In both PBC 
and PSC, the progressive structural damage of the intrahepatic biliary three leads to 
cholestasis.    
The histopathological features typical of PBC, including the extent of fibrotic development, 
have been proposed for the disease staging according to Ludwig [1]:  Stage I is characterised 
by bile duct injury and portal inflammation with minimal fibrosis (Figure 1-C); Stage II by 
expansion of portal tracts, periportal fibrosis and further inflammation; Stage III by fibrous 
septa, bridging fibrosis, and progressive ductopenia; Stage IV by cirrhosis (Figure 1-E, F). 
Recently, Nakanuma et al. [2], have proposed a new grading and staging system for PBC. In 
addition to the fibrosis, other two items (bile duct loss and deposition of orcein positive 
granules, which are characteristic of both PBC and PSC) constitute the basis of this new staging 
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system. Although the Ishak system (designed primarily to assess disease grade and/or stage 
in chronic hepatitis), the Ludwig and Nakannuma systems have been used to grade and stage 
histologic disease severity in PSC [3], at present there is no specific histologic scoring system 




Cholestasis and liver fibrogenesis 
The progressive structural damage of the intrahepatic biliary three leads to cholestasis, which 
has been traditionally considered an important pro-fibrogenic factor.  Indeed, bile salts are 
classically regarded as “cytotoxic” and their accumulation in liver tissue is thought to play a 
key role in determining liver cell necrosis and, then, in sustaining the development of liver 
fibrosis. Indeed, according to this paradigm, fibrogenesis in chronic cholestatic liver diseases 
could be seen as a classic chronic wound healing reaction similar to that observed in other 
fibrogenic chronic liver diseases. However, the concept of bile acid toxicity is at least in part 
based on studies performed on cultured hepatocytes by employing concentrations of bile 
salts in general largely exceeding the pathophysiological range.  In addition, some studies 
have suggested that the accumulation of bile salts in liver tissue is responsible for a certain 
degree of hepatocellular apoptosis rather than necrosis [4].  
The possibility that bile acids could directly affect the pro-fibrogenic phenotype of hepatic 
stellate cells (HSC) and other extracellular matrix (ECM) producing cells, thus leading to a 
mechanism of direct fibrogenesis, i.e. independent of the wound healing reaction, has been 
suggested by one study [5].  This study shows that bile acids bind to the epidermal growth 
factor receptor on HSC activating the protein kinase C/extracellular signal-regulated 
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kinase/p70S6K-dependent pathway thereby causing cell proliferation. However, this 
possibility remains controversial since other studies performed more recently and focused on 
nuclear receptors, FXR in particular, suggest that bile acids could modulate HSC activity by 
restoring peroxisome proliferator-activated receptor (PPAR) signalling and by FXR-SHP-
dependent inhibition of AP-1 signalling on downstream pro-fibrogenic targets [6].  
 
Overall, it appears that “pure” intrahepatic cholestasis in the absence of hepatocellular 
damage, lobular inflammation and bile duct damage and/or proliferation, is not associated 
with marked and/or progressive liver tissue fibrosis. Although it could be argued that most 
causes of intrahepatic cholestasis are generally short-lasting (i.e. drug-induced), or not 
continuous (i.e. benign recurrent cholestasis), it is quite evident that a significant fibrogenic 
reaction occurs only when the pathological process involves the structure of the bile duct and 
the cellular phenotype of cholangiocytes. 
Fibrogenic cells in biliary fibrosis 
In conditions of chronic liver damage, as well as following prolonged culture on plastic, HSC 
undergo a process of activation from the quiescent "storing" phenotype to the highly 
proliferative "myofibroblast-like" phenotype. However, the simple paradigm that fibrosis and 
tissue scarring are only due to the activation and progressive hyperplasia of HSC does not fully 
satisfy the features of biliary fibrosis. Indeed, it has become increasingly clear that pro-
fibrogenic myofibroblasts are a heterogeneous population of cells and do not derive entirely 
from quiescent HSC [7,8]. Portal fibroblasts (PF) located in the connective tissue around portal 
tracts appear to be of particular importance in ischemic and cholestatic liver disease and are 
different from HSC with regards to expression of marker proteins and response the pro-
 
6 Pinzani M – Biliary Fibrosis 
fibrogenic and mitogenic stimuli [9]. Therefore, it is reasonable to suggest that PF could 
represent the “first responders” in biliary fibrosis, later to be superseded by activated HSC 
when the pathological process involves the lobular area [10]. Overall, PF constitute the 
mesenchymal component of the intraportal bile ducts and it is possible that they undergo a 
phenotypical modulation similar to that of HSC in situation characterised by a derangement 
of the epithelial-mesenchymal interface typical of PBC and PSC. A better understanding of the 
differences between HSC and PF as regards their relative contribution to fibrosis and their 
molecular regulation could have significant implications for the development of antifibrotic 
therapies and even more for the discovery of disease-specific biomarkers.  
Role of bile acid and membrane lipid peroxidation in the fibrogenic evolution of chronic 
cholestatic diseases 
While the direct pro-fibrogenic role of bile acids is uncertain, consolidated experimental 
evidence suggests the involvement of reactive oxygen species (ROS) and free radical reactions 
in the pathogenesis of cholestatic liver injury [11-13]. Along these lines, it is of particular 
relevance to demonstrate lipid peroxidation by-products in liver tissue obtained from patients 
with PBC and such with cholestasis induced by extrahepatic obstruction of the biliary tree 
[14]. As suggested by pioneer in vitro studies, ROS and reactive aldehydes originating from 
the lipid peroxidation process may exert direct fibrogenic effects on activated HSC [15-17].  It 
is therefore possible that bile salts may indirectly affect ECM production by inducing lipid 
peroxidation in liver tissue as a consequence of their excessive accumulation.  
Liver tissue fibrosis occurring in chronic cholestatic diseases is characterised by different key 
features likely depending on the aetiology and the mechanisms of the disease. The main 
pathophysiological settings are illustrated in Figure 2.  
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Liver Fibrosis associated with bile duct damage/ductopenia. In PBC, interlobular bile ducts 
are surrounded and infiltrated by an inflammatory process occupying the portal tract. At later 
stages, inflammation extends to the lobule causing the formation of fibrous septa and finally 
the full blown picture of cirrhosis with nodular regeneration. The pattern of ECM 
accumulation in PBC is characterized by an increased expression of several collagenous and 
noncollagenous ECM components. Particularly, increased levels of mRNA encoding for 
collagens type I, III and IV have been demonstrated in mesenchymal cells of expanding portal 
tracts, fibrous septa and sinusoids of liver tissue obtained from patients with PBC [18-19]. The 
coexistence of a large inflammatory infiltrate with evident bile duct damage is consistent with 
the “inflammatory” nature of this disease: inflammation (lympho-mononuclear cells) likely 
represents the primary effector of bile duct injury. Infiltrating inflammatory cells, through the 
secretion of metalloproteinases (gelatinase), contribute to the degradation of the basal 
membrane like-ECM surrounding bile ducts which represent a potent stimulus for the 
activation of PF and HSC.  In this context, the release of inflammatory growth factors and 
cytokines by inflammatory cells provide the “fuel” for the proliferation of ECM-producing cells 
thus leading to the deposition of excessive fibrillar ECM. In other words, in PBC liver tissue 
fibrosis is a direct consequence of the primary inflammatory disturbance. In more advanced 
stages of the disease, the extension of fibrogenic process involves damaged and non-
damaged bile ducts as well as the periportal (or periseptal) sinusoidal system. This leads to 
marked cholestasis and progressive hepatocellular damage with further inflammatory 
infiltration, this time as a part of the tissue repair process leading to progressive scarring and 
nodular regeneration.  Indeed, in the advanced stage of the disease, the mechanisms leading 
to scar tissue formation greatly overlap with those involved in the pathogenesis of cirrhosis 
due to chronic hepatocellular damage. Along these lines, it is of interest the predominant 
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expression of tissue inhibitor of metalloproteinase I (TIMP-1) mRNA when compared to that 
of matrix metalloproteinase I (collagenase I; MMP-1) in liver tissue obtained from patients 
with chronic cholestatic liver diseases [20]. 
These aspects, which appear pathognomonic for PBC, are likely to occur, at least in the early 
phases, in PSC, where there is a clear derangement of the homeostasis of the biliary 
epithelium. However, due to the usual late diagnosis of PSC, these features are overtaken by 
the typical concentric peribiliary fibrosis. 
Liver fibrosis associated with bile duct proliferation. Cholestasis secondary to biliary tree 
obstruction, either intra- or extrahepatic, is usually associated with progressive liver fibrosis. 
Two key features appear to be relevant in this process: the proliferation of bile ducts and the 
direct or indirect contribution of bile salts to the fibrogenic process. The proliferation of bile 
ducts at the periphery of portal tracts that always follows biliary tree obstruction is attributed 
to proliferation of pre-existing ductules and/or differentiation of liver cell plates into biliary 
type structures, i.e. “ductular metaplasia” or more commonly “ductular reaction”.  Ductular 
reaction is a dynamic, multicellular reparative system that includes mesenchymal and 
inflammatory cells accompanying the expansion of the epithelial cells lining the smallest 
ramifications of the biliary tree, in continuity with the canals of Hering, which is the niche 
where the hepatic progenitor cells (HPC) is thought to reside. Expansion of the HPC 
compartment is a compensatory mechanism of liver repair, activated when proliferative 
ability of hepatocytes is compromised because of a severe liver damage [21,22]. Ductular 
reaction accompanied changes in the surrounding mesenchymal stroma comprise, among 
others, activation and proliferation of HSC and active deposition of fibrillar ECM occur [18,23].  
It is still unclear whether the changing epithelial phenotype directly induces an alteration of 
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the immediately adjacent mesenchymal cell biology and ECM, or whether a more fibrotic ECM 
induces the epithelial shift in differentiation. It is possible that this constitutes a two-way 
mechanism with relative predominance in different albeit similar conditions: biliary duct 
proliferation consequent to primary obstruction of the biliary tree is then followed by ECM 
changes (necessary to allow parenchymal “invasion” of newly formed bile duct), whereas bile 
duct neoformation present in fibrous septa of cirrhotic liver, independent of the etiology,  is 
consequent to the remarkable changes in ECM composition observed in this condition.  
Regardless, it is evident that ductular cells play a key role in the re-arrangement of the 
epithelial-mesenchymal interface. Indeed, cholangiocytes express a “reactive” phenotype 
(ductular reactive cells, DRC) and acquire the ability to produce cytokines, chemokines, 
growth factors, and angiogenic factors and to express a rich repertoire of receptors typically 
displayed by ductal plate cells in the early stages of liver development [24]. These phenotypic 
changes typical of DRC lead to the establishment of powerful paracrine communications with 
multiple stromal cell types, including PF and HSC, inflammatory cells, and Kupffer and 
endothelial cells [25]. 
The possibility that DRC are able to directly contribute to fibrogenesis through epithelial-to-
mesenchymal transition (EMT) has been suggested on the basis of the expression of 
mesenchymal cell markers.  These phenotypical changes are sustained by the need to acquire 
intercellular independence, motility and achieve a high degree of cell plasticity. DRC move 
from the HPC niche towards the site of damage by interacting with other inflammatory and 
mesenchymal cell elements, thus building up the ductular reaction [26]. However, DRC lack 
the ability to actively secrete ECM components, such as type I or type IV collagen, and must 
cooperate with other effector cells by stimulating their pro-fibrotic activities [27,28].  
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Concentric “onion-like” peribiliary fibrosis in PSC. The development of liver fibrosis in PSC 
presents a very peculiar pattern characterised by concentric “onion-like” fibrosis with a 
progressive obliteration of the bile ducts. Interestingly, this type of fibrotic development 
suggests the contribution of a pro-fibrogenic focus originating from the cholangiocyte layer 
leading to the concentric recruitment and activation of pro-fibrogenic cells from the portal 
stroma and from the neighboring lobular area.  It is of interest that the scarring typical of PSC 
has been compared to atherosclerosis [29] and the paracrine profibrogenic potential of 
activated cholangiocytes (there is not significant DRC in advanced PSC) compared to that of 
the activated endothelium in atherosclerosis. It is important to observe that a similar 
concentric “onion-like” fibrotic development is typical also of kidney and lung vascular 
strictures of scleroderma [30] where the pathogenesis involves the presence of peri-arterial 
vasculitis and a consequent ischemia of the vessel wall. Along these lines the potential role of 
vascular injury with ischemia of bile duct epithelium cells in the development of sclerosing 
cholangitis is supported by animal models of endothelial cell injury showing close 
morphological similarities with human PSC [31]. 
 
In conclusion, the available knowledge indicates that the development of biliary fibrosis is 
complex and its understanding requires the analysis of several coordinated cellular and 
biochemical mechanisms. The biology of cholangiocytes in health and disease is becoming 
more and more fascinating and the search of therapeutic targets and biomarkers even more 
challenging. Although, rapid progresses have been made in recent years, biliary fibrosis is 
definitely one of the areas of high demand in Hepatology.  
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FIGURE LEGENDS 
 
Figure 1. Photomicrographs of characteristic histopathological features of chronic biliary disease. A. 
Cytokeratin 7 immunostaining showing florid duct lesions in early PBC (Ludwig stage I): damaged CK7+ 
interlobular bile ducts (arrows) are infiltrated and surrounded by dense CK7- inflammatory cells. B. 
Cytokeratin 7 immunostaining showing ductopenia: no CK7+ native bile ducts are seen within the 
portal tract (PT); CK7 positivity highlights instead the marginal ductular reaction (large arrows), closely 
associated with numerous CK7+ periportal cells (small arrows) with an intermediate hepatobiliary 
phenotype. C. Early PSC showing an interlobular bile duct surrounded by a cuff of concentric fibrous 
tissue with “onion-skin” appearance (arrow). D. Late PSC showing a fibro-obliterative scar (FS) 
replacing the bile duct in a large portal tract. E. Biliary cirrhosis (Ludwig stage IV) showing regenerative 
nodules (RF) surrounded by fibrous septa (FS) with typical peripheral halo (arrows). F. Orcein stain 
showing biliary cirrhosis with characteristic prominent deposition of coarsely granular dark brown 
pigment representing copper-associated protein within the periseptal hepatocytes. 
 
 
Figure 2.  Main pathophysiological settings in the pathogenesis of biliary fibrosis. EMT: 
epithelia-mesenchymal transition; DRC: ductular reactive cells.   
 
 
 
 
